Allarity Therapeutics (ALLR) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.6 million), about 1.0 times the size. Bolt Biotherapeutics converts more of its revenue into profit, with a net margin of -433.7% versus -3509.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | BOLT |
|---|---|---|
| Share price | $0.785 | $4.91 |
| Market cap | $12.56M | $12.80M |
| 1-day change | -9.25% | -2.96% |
| YTD return | -27.31% | — |
| 1-year return | -25.94% | — |
| EPS (TTM) | $-0.79 | $-14.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.00K | $7.70M |
| Revenue growth (YoY) | — | +0.07% |
| Net income (latest FY) | $-11.23M | $-33.38M |
| Operating margin | -3939.06% | -469.30% |
| Net margin | -3509.69% | -433.74% |
| 52-week high | $1.84 | $7.78 |
| 52-week low | $0.769 | $3.10 |
| Distance from 52-week high | -57.34% | -36.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +1301.27% | +490.63% |
| Average volume | 131.74K | 257.43K |
| Shares outstanding | 16.00M | 2.61M |
| Employees | 7 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bolt Biotherapeutics is more profitable, keeping -433.7 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ALLR vs BOLT FAQ
Which is bigger, Allarity Therapeutics or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.56M for Allarity Therapeutics (ALLR).
Are Allarity Therapeutics and Bolt Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.